Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping
Sotatercept And MK-0616 Both Blockbuster-Tipped
Executive Summary
Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.
You may also be interested in...
Merck Points To Antibody-Drug Conjugate Potential During Another Growth Quarter
Keytruda brought in its usual stacks of cash, but Merck’s Q3 earnings call focused largely on a recent alliance with Daiichi Sankyo and the pharma’s growing emphasis on cancer ADCs.
Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables
The drug maker announced the start of a Phase III program for its oral PCSK9 inhibitor MK-0616, including a 14,550-patient outcomes trial set to start later in the year.
X4 Pharma’s Success After Cutbacks Will Comfort Hard-Hit Biotechs
X4 Pharma has shown that cutting back and focusing on a lead asset can work but mavorixafor’s first-in-class status and efficacy profile is not common.